Benjamin Challis

List of Publications by Year
in descending order

34 papers	999 citations	567281 15 h-index	454955 30 g-index
37 all docs	37 docs citations	37 times ranked	1773 citing authors

#	Article	IF	Citations
1	An approach to a patient with primary hyperparathyroidism and a suspected ectopic parathyroid adenoma. Journal of Clinical Endocrinology and Metabolism, 2022, , .	3.6	4
2	Metabolic dysfunction-related liver disease as a risk factor for cancer. BMJ Open Gastroenterology, 2022, 9, e000817.	2.7	10
3	Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort. Clinical Endocrinology, 2022, 97, 448-459.	2.4	4
4	Breast cancer in multiple endocrine neoplasia type 1 (MEN1). Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	2
5	Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes. Surgery, 2021, , .	1.9	10
6	Rare variant contribution to human disease in 281,104 UK Biobank exomes. Nature, 2021, 597, 527-532.	27.8	224
7	Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature review. Endocrine Oncology, 2021, 1, 33-44.	0.4	0
8	A single centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism. Endocrine Connections, 2021, 10, 1435-1444.	1.9	2
9	Precision Medicine in Phaeochromocytoma and Paraganglioma. Journal of Personalized Medicine, 2021, 11, 1239.	2.5	7
10	Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans. Clinical Cancer Research, 2020, 26, 391-396.	7.0	11
11	A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma. Clinical Endocrinology, 2020, 93, 528-538.	2.4	36
12	Response to Letter to the Editor: â€œCT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentalomaâ€• Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3842-e3843.	3.6	0
13	HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol. BMJ Open, 2020, 10, e033923.	1.9	1
14	P0347COMPLEMENT FACTOR BB AND FACTOR C4D IN IGA NEPHROPATHY AND IGA VASCULITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
15	Genetic testing for hereditary hyperparathyroidism and familial hypocalciuric hypercalcaemia in a large UK cohort. Clinical Endocrinology, 2020, 93, 409-418.	2.4	27
16	SDHC epi-mutation testing in gastrointestinal stromal tumours and related tumours in clinical practice. Scientific Reports, 2019, 9, 10244.	3.3	20
17	What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?. Clinical Endocrinology, 2019, 91, 708-715.	2.4	14
18	Characterisation of proguanylin expressing cells in the intestine â€“ evidence for constitutive luminal secretion. Scientific Reports, 2019, 9, 15574.	3.3	8

#	Article	IF	Citations
19	Clinical Practice Guidance: Surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers. Clinical Endocrinology, 2019, 90, 499-505.	2.4	25
20	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 312-318.	3.6	96
21	A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway. Journal of Allergy and Clinical Immunology, 2018, 142, 311-314.e6.	2.9	13
22	Translating In Vivo Metabolomic Analysis of Succinate Dehydrogenaseâ€“Deficient Tumors Into Clinical Utility. JCO Precision Oncology, 2018, 2, 1-12.	3.0	22
23	Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab. Seminars in Oncology, 2018, 45, 151-155.	2.2	19
24	Peptidomic analysis of endogenous plasma peptides from patients with pancreatic neuroendocrine tumours. Rapid Communications in Mass Spectrometry, 2018, 32, 1414-1424.	1.5	32
25	A case of a metastatic SDHA mutated paraganglioma re-presenting twenty-three years after initial surgery. Endocrine-Related Cancer, 2017, 24, L69-L71.	3.1	10
26	Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4013-4022.	3.6	35
27	Adult-onset hyperinsulinaemic hypoglycaemia in clinical practice: diagnosis, aetiology and management. Endocrine Connections, 2017, 6, 540-548.	1.9	12
28	Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2. Clinical Endocrinology, 2016, 85, 306-312.	2.4	19
29	Familial Adrenocortical Carcinoma in Association With Lynch Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2269-2272.	3.6	27
30	Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150105.	0.5	7
31	Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation. Clinical Endocrinology, 2014, 81, 855-861.	2.4	21
32	Genetic Disorders of Insulin Action: Far More than Diabetes. Current Obesity Reports, 2013, 2, 293-300.	8.4	1
33	A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Human Molecular Genetics, 2002, 11, 1997-2004.	2.9	249
34	Past, present and future strategies to study the genetics of body weight regulation. Briefings in Functional Genomics & Proteomics, 2002, 1, 290-304.	3.8	15